Stina Oredsson

Stina Oredsson


Personal profile


An increasing amount of evidence suggests that the major culprit of cancer relapse is cancer stem cells (CSCs). Conventional chemotherapy appears to target bulk cancer cells, while CSCs on the other hand survive and may initiate new tumours. Thus, finding new therapies that target CSCs is important. In our research we are investigating the effect of a variety of molecules on bulk cancer cells and CSCs. Through cooperation with chemists, we have access to a library of salinomycin analogues. Salinomycin is a polyether antibiotic that was shown to be 100 times more efficient in inhibiting CSCs than the conventional chemotherapeutic drug paclitaxel. We have shown that synthetically modified salinomycin analogues are more efficient against CSCs than salinomycin and we are now evaluating the adverse outcome pathway of these compounds. We have cooperation with research groups in Bolivia and Ethiopia evaluating the cancer cell and CSC effect of compounds isolated from plants used in traditional medicine. As experimental system, we are using human cancer cell lines as well as normal cell lines. The concept of normal cell toxicity testing in vitro is central to our research and we think it is important to try to elucidate side effects before injecting toxic drugs into tumour bearing animals. We are in the process of developing a 3D system of electrospun fibers combined with extra cellular matrix components for co-cultivation of cancer cells and normal cells for drug testing.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

UKÄ subject classification

  • Cancer and Oncology

Free keywords

  • Cancer stem cells
  • cancer cell lines
  • research without animals


Dive into the research topics where Stina Oredsson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or